CJC-1295 serum proteins
A peptide engineered to stay in circulation also gives the rest of the blood sample something to report.
The albumin attachment
The engineering is ingenious. CJC-1295 starts with the active GHRH fragment, adds four stabilizing amino-acid substitutions and, in the DAC form, gains an attachment that binds serum albumin. Albumin is an abundant blood protein. That attachment helps explain the prolonged hormone response in the healthy-adult CJC-1295 study.
The name commonly gets applied to a different preparation too: Modified GRF (1-29), described as no-DAC, lacks the albumin-binding attachment and acts for a much shorter time. The distinction is essential. CJC-1295's albumin attachment impresses me as chemistry; extra exposure still needs a clinical justification.
The CJC-1295 duration measurements
In healthy adults aged 21-61, single CJC-1295 administrations produced 2- to 10-fold increases in mean GH for six days or more, and 1.5- to 3-fold increases in IGF-1 for 9-11 days. Estimated peptide half-life was 5.8-8.1 days. After multiple study administrations, IGF-1 remained above baseline for up to 28 days.
Half-life describes the peptide's disappearance; the IGF-1 interval describes a downstream response. In a separate study of healthy men aged 20-40, GH pulse frequency and magnitude persisted despite a rise in basal GH. The persistence of pulses is interesting physiology. Clinical outcomes and long-term safety still require their own trials.
Exploratory protein markers
The exploratory serum protein study in 11 healthy young men adds a different kind of observation. Apolipoprotein A1 and a transthyretin isoform decreased; an albumin fragment and immunoglobulin-related species increased. The immunoglobulin/albumin-fragment signal correlated with IGF-1. These were candidate markers of stimulation.
I hesitate to rank the individual changes as good or bad. The paper gives them a possible analytical use, while their clinical meaning remains unsettled. The serum protein result widens the question: the headline hormone measurement captured only some of what was changing. The clinical meaning of those wider protein changes remains unresolved.
Development and safety
CJC-1295 has never been approved for human use. Its Phase 2 development program in HIV-associated visceral obesity was discontinued. FDA's 2024 Pharmacy Compounding Advisory Committee review did not recommend it for the 503A compounding bulks list, citing immunogenicity and other safety concerns. Immunogenicity means the possibility of an immune response to the peptide.
The early hormone studies leave a small and short human record, and the GHRH review places the long-acting approach in a wider pharmacological context. Sustained GH and IGF-1 stimulation raises questions about glucose handling, fluid retention and long-term growth-related risks. CJC-1295 is prohibited at all times in sport under WADA S2.
Analytical work has identified CJC-1295 in an unknown pharmaceutical preparation. That chemical identification establishes what was in that sample; it cannot certify other preparations. I consider the unresolved safety history and the limited efficacy record substantial reasons to resist confident wellness claims.
Community sleep and swelling accounts
Community descriptions include deeper sleep, quicker recovery and a leaner appearance, alongside water retention, swollen hands or face, tingling and local irritation. These are anecdotal accounts, not clinical evidence. Some accounts involve combinations or confuse DAC with no-DAC, so even attribution to CJC-1295 is uncertain.
The sermorelin comparison separates the hormone findings from claims about body composition. Tesamorelin's HIV-associated fat studies supply a more developed clinical record for a different molecule and population.